Multiple sclerosis is an immune-mediated disease characterized by the demyelination of nerve fibers within the central nervous system, leading to a spectrum of neurological symptoms and long-term disability. Affecting over two million individuals worldwide—approximately 150,000 in the UK alone—MS presents varying clinical trajectories influenced by both genetic predispositions and environmental factors. Despite its global impact, most prior genetic investigations of MS risk have been limited to populations of European ancestry, potentially overlooking critical variants prevalent in other ethnic groups.

The investigative team leveraged genomic data from more than 3,000 MS patients alongside a control cohort exceeding 27,000 individuals without MS. Participants were drawn predominantly from the ADAMS Project, a UK-based initiative specifically designed to enhance ethnic diversity in MS research cohorts, alongside data from the expansive UK Biobank. This meta-analytic approach enabled the researchers to perform high-resolution genetic association analyses, focusing keenly on the major histocompatibility complex (MHC) region—a locus pivotal in immune function and previously implicated as a key contributor to MS susceptibility.

Intriguingly, the study found that MHC variants were strongly associated with MS risk not only in individuals of European descent but also in those of South Asian and African ancestry. This reinforces the notion that common immunogenetic pathways are central to MS pathology across populations. The immune mechanisms implicated by these variants suggest a conserved biological underpinning in the way the disease develops, regardless of ancestral background.

However, the analysis also revealed subtle but significant differences in genetic variant frequencies and effects among ancestries. Notably, the researchers identified a protective genetic variant that is relatively frequent in South Asian populations yet rare in Europeans. Such ancestry-specific variants likely elude detection in genetic studies confined to homogeneous European cohorts, underscoring an intrinsic bias in previous research methodologies. This novel finding reveals the complex interplay of diverse genetic factors that modulate susceptibility and resistance to MS within different ethnic groups.

Crucially, the study demonstrated that while many MS-associated variants discovered in European populations are also present in South Asian and African groups, the magnitude and direction of their effects vary. This observation suggests that although the overarching disease mechanisms may be shared, the precise genetic architecture—and, by extension, risk prediction models—may require tailoring to individual ancestries for accurate clinical applicability. This nuance has profound implications for advancing personalized medicine in MS.

Beyond genetics, MS disparities manifest clearly in disease outcomes. Prior epidemiological studies have shown that individuals from Black ethnic backgrounds frequently experience a more aggressive disease course, with increased disability and poorer prognoses compared to their White counterparts. The present study acknowledges that genetic differences alone cannot fully account for these disparities, emphasizing the importance of social determinants of health, healthcare access, and potential biases in diagnosis and treatment.

One consequence of the longstanding underrepresentation of diverse populations in MS genetics is the potential for misdiagnosis or delayed diagnosis among minority groups. This gap not only affects patient care but also limits the reliability of genetic risk profiling tools developed predominantly from European data. Consequently, predictive models and therapeutic interventions may perform inadequately in non-European populations, perpetuating health inequities.

The empowerment of diverse participant inclusion in research—exemplified by the ADAMS Project—aims to rectify these historical limitations. By broadening the scope of genetic inquiry, researchers can unmask previously obscured risk factors, refine disease understanding, and build more equitable prediction algorithms. As Dr. Benjamin Jacobs, clinical lecturer and co-author, articulates, expanding ancestral representation enables the discovery of critical insights that remain hidden in monolithic datasets.

Dr. Ruth Dobson, the study’s lead investigator and Professor of Clinical Neurology, highlights the dual imperative of fairness and scientific integrity underpinning this research. She stresses that excluding vast segments of the global population from genetic studies impedes comprehensive knowledge acquisition and innovation. Inclusive research fosters both ethical responsibility and superior scientific outcomes.

The MS Society, represented by Senior Research Communications Manager Caitlin Astbury, echoes the necessity of diversity in research participation. They emphasize that MS affects individuals across all ethnicities and backgrounds, demanding that genetic and clinical studies reflect this reality to ensure balanced progress in treatment, diagnosis, and risk assessment advancements.

This study’s findings propel the MS research field toward more holistic and representative genetic explorations, paving the way for tailored therapeutic strategies. It simultaneously serves as a clarion call to dismantle the Eurocentric bias that has historically constrained our understanding of complex diseases. Enhanced genetic diversity in research cohorts promises to yield a more nuanced appreciation of MS pathogenesis and improve health equity globally.

In summary, Queen Mary University of London’s team provides compelling evidence that multiple sclerosis shares foundational genetic determinants across diverse ancestries, while also revealing population-specific variants that can profoundly influence risk and clinical application. The study advocates for an urgent transformation in genetic research paradigms, prioritizing inclusivity to optimize patient outcomes and elevate scientific rigor.

Subject of Research: People
Article Title: Genetic Determinants of Multiple Sclerosis Susceptibility in People From Diverse Ancestral Backgrounds
News Publication Date: 6-Mar-2026
Web References:

• ADAMS Project: https://app.mantal.co.uk/adams
• Related BMJ Open Study: https://bmjopen.bmj.com/content/13/5/e071656
  References:
  Jacobs, B., et al., “Genetic determinants of Multiple Sclerosis susceptibility in people from diverse ancestral backgrounds,” Neurology, DOI: 10.1212/WNL.0000000000214708
  Keywords: multiple sclerosis, genes, diversity, ethnicity, ancestry, immune disorders, genetic analysis, medical genetics, genomics

Precision medicine, which aims to provide tailored healthcare solutions based on individual genetic profiles, is currently hampered by “ancestral bias” in genetic data. This bias emerges primarily because a disproportionate amount of genetic research relies on datasets derived from a single or limited ancestral group, primarily individuals of European descent. The consequences of this oversight are dire; it not only stymies the development of effective medical treatments but also exacerbates health disparities for diverse populations. The underrepresentation of many global communities means that healthcare solutions derived from existing research often do not apply to them, leaving significant gaps in understanding and addressing their health needs.

In response to this challenge, Dr. Graim and her research team have developed an innovative machine-learning tool called PhyloFrame. This advanced computational tool leverages artificial intelligence to systematically account for ancestral diversity in genetic data, merging large-scale population genomics databases with smaller disease-specific datasets. The ultimate aim of PhyloFrame is to enhance the accuracy and effectiveness of disease prediction, diagnosis, and treatment for everyone, irrespective of their genetic background. With substantial funding from the National Institutes of Health, the team is poised to reshape precision medicine’s approach to genetic diversity.

PhyloFrame’s capabilities are particularly crucial in today’s health landscape, where understanding genetic risk factors can greatly influence treatment paths for diseases such as cancer. The tool is designed to identify subtle genetic differences among disease subtypes—like various forms of breast cancer—thereby enabling the development of personalized treatment strategies for each patient based on their unique genetic composition. The depth of analysis required for such predictions demands substantial computational resources, which is why the researchers utilize the University of Florida’s HiPerGator supercomputer, one of the most advanced computing systems available in the United States.

The journey toward creating PhyloFrame stemmed from a pivotal conversation Dr. Graim had with a physician frustrated by the limited relevance of existing genetic studies to his multitude of diverse patients. This interaction sparked Dr. Graim’s resolve to explore how machine learning could address the disconnect between research data and real-world patient populations. Driven by a commitment to bridge this gap, she has devoted her research to advancing the field of population genomics, ultimately harnessing machine learning techniques to make progress in equitable healthcare.

Initially, PhyloFrame began as a modest project utilizing basic machine learning models to display the impact of incorporating diverse population genomic data. However, the initial success has laid the groundwork for securing additional funding and support to develop more sophisticated models. The importance of this initiative cannot be overstated, as it seeks to redefine how populations are characterized in medical research, moving away from a one-size-fits-all approach, and emphasizing the need for data that mirrors the true genetic diversity present in the population.

One of the fundamental aspects that makes PhyloFrame unique is its capacity to maintain the accuracy of predictions across various populations. Traditional precision medicine models have often been criticized for relying on data that may not accurately reflect the genetic makeup of the broader population. This is particularly concerning when many existing datasets are amassed from research hospitals that primarily serve patients who are more likely to trust the healthcare system. Consequently, those from rural areas or marginalized groups frequently miss out on being represented in genetic studies, further complicating efforts to develop universally applicable medical treatments.

Notably, Dr. Graim’s research indicates that up to 97% of the genetic samples sequenced originate from individuals of European ancestry, a phenomenon that can be traced back to national and state funding patterns, methodological preferences in genomic studies, and socioeconomic factors that influence healthcare access. For instance, those lacking insurance coverage may find it incredibly challenging to obtain both treatment and genetic sequencing, illustrating how deeply interconnected social and health dynamics can affect research outcomes.

Countries such as China and Japan are also making strides to enhance diversity in genetic databases; however, there still exists a significant gap when compared to the wealth of data available from European populations. Disadvantaged and economically poorer communities remain underrepresented, raising further concerns about equitable access to both treatment and research opportunities. In light of this, Dr. Graim emphasizes that having diverse training data is not only crucial for improving the models for underrepresented groups but also beneficial for European populations, as it prevents the risk of overfitting models.

The ultimate goal of the PhyloFrame initiative is to ensure that advanced machine-learning tools are not only applicable in research settings but also feasible for clinical application. Dr. Graim envisions a future where clinicians can use sophisticated models to tailor treatment plans to patients based on their unique genetic profiles. This kind of personalized approach to medicine could significantly improve health outcomes while minimizing adverse effects associated with treatments that may not be effective for certain patient groups.

As the team embarks on refining PhyloFrame and expanding its applicability to additional diseases, Dr. Graim remains hopeful that these transformative methods will usher in a new era of precision medicine. The intended outcome is clear: to facilitate early diagnosis tailored to individual genetic makeup and to optimize treatment strategies that deliver maximum efficacy with minimum side effects. The researchers are ardently committed to achieving the ideal of providing the right treatment to the right person at the right time, an objective that encapsulates the essence of precision medicine.

The PhyloFrame project has also garnered backing from the UF College of Medicine Office of Research’s AI2 Datathon grant award, signifying institutional recognition and support for innovative research endeavors aimed at harnessing artificial intelligence to improve human health prospects. As this exciting research continues to unfold, the implications for not just precision medicine, but for the landscape of genetic research as a whole, are profound.

The innovative strides taken by Dr. Graim and her team at the University of Florida embody a critical turning point in genetic research, ensuring that greater representational equity leads to improved health outcomes across diverse populations. As the narrative of precision medicine evolves, it is imperative that these efforts continue to gain traction, fostering an inclusive approach that attends to the healthcare needs of every segment of the global populace.

Subject of Research: Ancestral bias in genetic data
Article Title: Equitable machine learning counteracts ancestral bias in precision medicine
News Publication Date: [Insert Date]
Web References: [Insert URL]
References: [Insert References]
Image Credits: [Insert Credits]

Keywords